Bottom line
A marketed growth-hormone-axis combination pairing a substance labeled “CJC-1295 (no DAC)” with GHRP-2 (pralmorelin), a hexapeptide ghrelin-receptor agonist. GHRP-2 has an approved product-specific diagnostic role in Japan, but no published controlled study of this combination was identified.
No established or recommended human dose.
Name and formulation variability
| Market observation (source/date) | Claimed components and amounts | Exact identity independently verified? | Verification limits |
|---|---|---|---|
| Online-market listings observed in 2026 | Substance labeled “CJC-1295 (no DAC)” plus GHRP-2; variable amount | No | Seller-declared identity and amount are not independent verification |
Also known as: CJC-1295/GHRP-2, Mod GRF 1-29/GHRP-2, CJC-1295+ GHRP-2. GHRP-2: Pralmorelin (INN), GPA-748, KP-102.
Critical ambiguity: the clinical-study name CJC-1295 refers to the DAC conjugate designed for albumin binding. Online-market “CJC-1295 no DAC” usually refers to Modified GRF 1-29, a different substance. Evidence for CJC-1295 DAC cannot be transferred to Modified GRF 1-29 or this blend.
The marketed CJC-1295 no-DAC substance is a different identity from clinical-studied CJC-1295 with DAC. GHRP-2 or pralmorelin has separate small human-study evidence and a product-specific diagnostic status in Japan. Neither status nor separate evidence authorizes or tests the market blend.
Component evidence
| Component | Separate evidence | Combination evidence | Compatibility |
|---|---|---|---|
| CJC-1295 no DAC | Human evidence: no controlled study identified. Regulatory record: no product-specific authorization identified. Limitations: GHRH-receptor/cAMP activity is inferred from sequence and class rather than demonstrated for this standalone substance. | Not identified | No published stability data |
| GHRP-2 / pralmorelin | Human evidence: small, indication-specific studies measured GH-axis, pituitary-hormone, and food-intake endpoints. Regulatory record: PMDA lists a pralmorelin hydrochloride diagnostic product in Japan. Limitations: the product, jurisdiction, and diagnostic indication do not transfer to this blend. | Not identified | Not identified |
The component evidence is limited and indication-specific. Arvat et al. studied six young adults and six older adults given GHRP-2 or hexarelin Administered into a vein. Source de la définition: Neutral gloss; usage context: Routes, devices, and absorption primer · Glossaire at 1 or 2 mcg/kg and reported GH release plus small ACTH, cortisol, and prolactin responses. Laferrère et al. used a randomized within-subject comparison in seven lean healthy men; a 270-minute Administered into the tissue layer under the skin. Source de la définition: Neutral gloss; usage context: Routes, devices, and absorption primer · Glossaire GHRP-2 infusion at 1 mcg/kg/hour increased food intake by 35.9% versus saline. Neither study tested Modified GRF(1-29), CJC-1295, or this blend.
Combination-specific studies
A targeted PubMed search through 2026-08-06 identified no published human A study in which participants are assigned to the study material or a comparator by chance. Source de la définition: Neutral gloss; usage context: Evidence grading methodology · Glossaire or controlled animal study of the specific CJC-1295 + GHRP-2 combination.
Safety and interaction uncertainties
GHRP-2 elevates ACTH, cortisol, and prolactin — confounding GH-axis readouts
Appetite stimulation may confound metabolic studies
No combination-specific safety data
Theoretical mitogenic concern from sustained GH/IGF-1 elevation
Regulatory and product-quality notes
Neither component FDA-approved for therapeutic use
PMDA lists GHRP Kaken 100 (pralmorelin hydrochloride), approved in Japan for diagnosis of growth-hormone secretory deficiency; this product-specific diagnostic authorization does not apply to the blend
The 2026 The World Anti-Doping Agency; its Prohibited List classifies many peptides as prohibited substances in sport. Source de la définition: WADA and sport regulation brief · Glossaire List explicitly names CJC-1295 among GHRH analogues and GHRP-2 (pralmorelin) among GH-releasing peptides in section S2.2.4; both are prohibited at all times
An online “research use only” label is not authorization for human use
Evidence gaps
No combination study (human or animal)
No dose-ratio optimisation data
No long-term safety data for the combination
Corticosteroid elevation complicates interpretation of any study using this blend
For jurisdiction context, see Japan regulation. Compare CJC-1295 + Ipamorelin and CJC-1295 + GHRP-6; the WADA page addresses the independent sport-status axis.
Sources
Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. https://pubmed.ncbi.nlm.nih.gov/16352683/
Pihoker C, et al. Pharmacokinetics and pharmacodynamics of GHRP-2 in children. J Clin Endocrinol Metab. 1998;83(4):1168-1172. PMID 9543135. https://pubmed.ncbi.nlm.nih.gov/9543135/
Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Peptides. 1997;18(6):885-891. PMID 9285939. https://pubmed.ncbi.nlm.nih.gov/9285939/
Laferrère B, et al. Growth hormone-releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. J Clin Endocrinol Metab. 2005;90(2):611-614. PMID 15699539. https://pubmed.ncbi.nlm.nih.gov/15699539/
Pharmaceuticals and Medical Devices Agency. GHRP Kaken 100 (pralmorelin hydrochloride), current product information and package insert. https://www.pmda.go.jp/PmdaSearch/rdDetail/iyaku/7223407D2023_1?user=1
World Anti-Doping Agency. 2026 Prohibited List, section S2.2.4. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf